Industries > Pharma > Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region

PUBLISHED: 01 December 2017
PAGES: 145
PRODUCT CODE: PHA0263

Clear
WOOCS 2.2.1
SKU: PHA0263 Categories: , ,

• Do you need definitive NASH market data?
• Succinct NASH market analysis?
• Technological insight?
• Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The increase in prevalence of hepatic pathology and its pathophysiology have propelled the growth of the novel therapeutic studies, which has given birth to the novel therapeutic solutions such as Farnesoid X Receptor (FXR) agonists, incretins and probiotics. Most of these studies are in last phase of their clinical trials and commercialization is expected within a short period of time that could be used in treating patients with NASH.

Report highlights

• 132 quantitative tables, charts, and graphs across 145 pages

• Global NASH market outlook and analysis from to 2027

• Global NASH submarket forecasts and analysis from to 2027
• GFT 505
• Obeticholic Acid (INT-747)
• Simtuzumab and Liraglutide (Victoza)
• Vitamin E
• Pioglitazone
• Placebo

• Regional and National NASH market forecasts to 2027
• North America forecast to 2027:
• US forecast to 2027
• Canada forecast to 2027
• Mexico forecast to 2027

• South America forecast to 2027:
• Brazil forecast to 2027
• Argentina forecast to 2027
• Paraguay forecast to 2027
• Bolivia forecast to 2027
• Rest of South America forecast to 2027

Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

• Europe forecast to 2027:
• Germany forecast to 2027
• UK forecast to 2027
• France forecast to 2027
• Italy forecast to 2027
• Spain forecast to 2027
• Rest of Europe forecast to 2027

• Asia-Pacific forecast to 2027
• Japan forecast to 2027
• India forecast to 2027
• China forecast to 2027
• Australia forecast to 2027
• Thailand forecast to 2027
• Rest of Asia-Pacific forecast to 2027

• Rest of World forecast to 2027:
• Middle East forecast to 2027
• Africa forecast to 2027
• Other Countries forecast to 2027

Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Nonalcoholic Steatohepatitis (NASH)
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Banks

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Nonalcoholic Steatohepatitis (NASH) Market Report to 2027


Download sample pages

Complete the form below to download your free sample pages for Nonalcoholic Steatohepatitis (NASH) Market Report to 2027


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories